Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
The Lancet. Haematology
|
June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology
|
April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
The New England Journal of Medicine
|
July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Cancer Cell
|
November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
The New England Journal of Medicine
|
October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
Alex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.
Blood Reviews
|
September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood
|
March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Uma Borate, Kelly Pugh, Allyson Waller, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Journal of the National Cancer Institute
|
April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Barbara A Conley, Lou Staudt, Naoko Takebe, et al.
Journal of the National Cancer Institute
|
January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Keith T Flaherty, Robert Gray, Alice Chen, et al.
The Lancet. Haematology
|
June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.
The Lancet. Haematology
|
April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
The New England Journal of Medicine
|
July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
Mark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Cancer Cell
|
November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
David A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.
The New England Journal of Medicine
|
October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
Alex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.
Blood Reviews
|
September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood
|
March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Uma Borate, Kelly Pugh, Allyson Waller, et al.
Page
of 11